<DOC>
	<DOCNO>NCT02293863</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study investigate safety clinical activity single intravenous ( IV ) dose MHAA4549A adult participant hospitalize severe influenza A combination oseltamivir versus comparator arm placebo oseltamivir .</brief_summary>
	<brief_title>A Study MHAA4549A Combination With Oseltamivir Versus Oseltamivir Participants With Severe Influenza A Infection</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Diagnosis influenza A Sponsorapproved influenza test use aid diagnosis . A Sponsorapproved influenza test include : Influenza antigen test Influenza polymerase chain reaction ( PCR ) test One follow marker severity within 24 hour admission : requirement O2 supplementation maintain SpO2 great ( &gt; ) 92 % ; requirement Positive Pressure Ventilation ( PPV ) A negative urine serum pregnancy test woman childbearing potential within 2 day prior study treatment Participants reproductive potential must agree use acceptable contraceptive measure per protocol minimum , local guideline , stringent Pregnant lactate woman , woman intend become pregnant study Hypersensitivity monoclonal antibody constituent ( sodium succinate , sucrose , polysorbate 20 ) study drug Hypersensitivity active substance excipients oseltamivir Investigational therapy within 30 day prior study treatment Received prior therapy antiinfluenza monoclonal antibody therapy ( include MHAA4549A ) within 8 month prior study treatment Current treatment ( within 7 day dose ) probenecid , amantadine rimantidine Participants take total 6 dos ( 3 dos peramivir ) antiinfluenza therapy ( e.g. , oseltamivir , zanamivir , laninamivir , peramivir ) period onset symptom prior study treatment Admission &gt; 48 hour prior study treatment Onset influenza symptom ( include fever , chill , malaise , dry cough , loss appetite , myalgia , coryza , nausea ) &gt; 5 day prior study treatment Positive influenza B influenza A + B infection within 2 week prior study treatment High probability mortality next 48 hour determine investigator Participants require home baseline oxygenation therapy Participants history chronic lung disease document SpO2 le ( &lt; ) 95 % oxygen Participants chronic dose corticosteroid exceed 10 milligram per day ( mg/day ) prednisone equivalent steroid dose duration great 14 day within 30 day entry study Participants follow significant immune suppression : bone marrow solid organ transplant previous 12 month ; cancer chemotherapy previous 12 month , HIV infection recent Cluster Differentiation 4 ( CD4 ) &lt; 200 cell per milliliter ( cells/mL ) , significant immune suppression determine investigator discussion Sponsor Medical Monitor Participants extracorporeal membrane oxygenation ( ECMO ) time randomization Any disease condition would , opinion site investigator Sponsor , place participant unacceptable risk injury render participant unable meet requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>